Associated tags: Benzoyl peroxide, Adapalene, Dermatology, Health, Perkinsus marinus, Skin, Cetaphil, Patient, Cosmetics, Galderma, Pharmaceutical industry, Safety, Pharmaceutical, Research, Biotechnology, Clinical Trials, Science
Locations: AUSTRALIA, MIDDLE EAST, SINGAPORE, ASIA PACIFIC, UNITED ARAB EMIRATES, AD, MISSISSIPPI, JAPAN, SWITZERLAND, EUROPE, CANADA, UNITED STATES, NORTH AMERICA, ARCADIA
Cosmetics,
Retail,
Pharmaceutical,
Health,
BofA Securities,
Citigroup,
Exercise,
COMMUNICATION,
UBS,
Sunlight,
ADIA,
Goldman Sachs,
IPO,
AMERICA,
Morgan Stanley,
BNP Paribas,
EQT,
Jefferies,
CHF,
NOT,
Calendar,
SIX,
Security (finance) Galderma Group AG (the “Company” or “Galderma”), the pure-play dermatology category leader, today announces that the Joint Global Coordinators exercised in full their option to purchase an additional 5,626,592 shares from Sunshine SwissCo AG (EQT), a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte.
Key Points:
- Galderma Group AG (the “Company” or “Galderma”), the pure-play dermatology category leader, today announces that the Joint Global Coordinators exercised in full their option to purchase an additional 5,626,592 shares from Sunshine SwissCo AG (EQT), a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte.
- Including the shares placed in connection with the over-allotment option, a total of 43,137,209 existing registered and newly issued registered shares have been sold in the IPO.
- Following the full exercise of the over-allotment option, the free float as calculated by SIX is expected to increase from 20.4% to 22.8%.
- Goldman Sachs International, Morgan Stanley and UBS acted as Joint Global Coordinators and Joint Bookrunners for the IPO.
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
Key Points:
- THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
- Galderma Group AG, the pure-play dermatology category leader, today announces the pricing of its Initial Public Offering at CHF 53 per share, at the top of the announced price range.
- The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange tomorrow, March 22, 2024.
- To access the full announcement on the public offering of securities of Galderma Group AG in Switzerland, for those legally permitted, please visit www.galderma.com/intentiontofloat .
General Health,
Alternative Medicine,
Other Health,
Health,
Pharmaceutical,
Face,
Hyaluronic acid,
Patient,
Research,
Restylane,
System,
Skin,
NEXT,
Consultant,
Botulinum toxin,
Neck Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024.
Key Points:
- Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024.
- “Galderma’s extensive activities at AMWC demonstrate our commitment to pushing the boundaries of injectable aesthetics, to anticipate and address tomorrow’s needs today.
- The event is taking place in Room Prince Pierre on Wednesday March 27, 2024, from 2:00 to 4:00 PM CET.
- Additional data spanning our leading neuromodulator portfolio, Alluzience and Azzalure, will be presented, as well as a new skin quality assessment scale and the AART-HIT™ approach for combining aesthetic products to maximize patient outcomes.
Retrieved on:
Wednesday, March 13, 2024
Cosmetics,
Retail,
Health,
Other Science,
General Health,
Research,
Science,
Public,
COMMUNICATION,
SIX Swiss Exchange,
AMERICA,
Prospectus,
NOT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Key Points:
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
- THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
- Galderma Group AG, the pure-play dermatology category leader, today announces the publication of its prospectus and the start of the book-building process, as part of its intention to conduct an Initial Public Offering on the SIX Swiss Exchange.
- To access the full announcement, please visit www.galderma.com/intentiontofloat .
Health,
Medical Devices,
Other Health,
Clinical Trials,
Research,
Science,
Biotechnology,
Dermatology Life Quality Index,
Atopic dermatitis,
Prurigo nodularis,
Nemolizumab,
Patient,
Sleep,
American Academy,
Quality of life,
European Medicines Agency,
Skin,
AAD,
FDA,
DLQI,
IGA,
Food,
Pharmaceutical industry Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.1 Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained skin and itch responses through to week 48, with similar efficacy observed whether receiving nemolizumab every four (Q4W) or eight weeks (Q8W).2 These late-breaking data are being presented today at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting, taking place on March 8-12, 2024.
Key Points:
- Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.1 Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained skin and itch responses through to week 48, with similar efficacy observed whether receiving nemolizumab every four (Q4W) or eight weeks (Q8W).2 These late-breaking data are being presented today at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting, taking place on March 8-12, 2024.
build and strengthen for these debilitating diseases, where symptoms
such as intense itch can put a significant burden on quality of life.
- response in prurigo nodularis and atopic dermatitis, respectively.”
69% of those who had received continuous nemolizumab treatment and 65% of nemolizumab-naïve patients had reached clearance or almost-clearance of skin lesions, as measured on the Investigator’s Global Assessment (IGA) score
Sleep disturbance, as measured by the sleep disturbance numerical rating scale (SD-NRS), also continued to improve, as well as quality of life, as measured by the Dermatology Life Quality Index (DLQI).1
Results also reinforced nemolizumab’s rapid onset of action, with nemolizumab-naïve patients rapidly achieving an at least four-point improvement in itch intensity, as measured by the PP-NRS, as early as week four, consistent with the continuous-nemolizumab cohort.
- Nemolizumab was also granted U.S. FDA Priority Review for prurigo nodularis.
- Further submissions to regulatory authorities in additional countries are planned in 2024.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Key Points:
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
- THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
- Galderma Group AG, the pure-play dermatology category leader, today announces its intention to conduct an Initial Public Offering on the SIX Swiss Exchange.
- To access the full announcement on the public offering of securities of Galderma Group AG in Switzerland, for those legally permitted, please visit www.galderma.com/intentiontofloat .
Retrieved on:
Thursday, February 29, 2024
Research,
Clinical Trials,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Cosmetics,
Retail,
Science,
Other Science,
Adapalene,
Education,
Investment,
Growth,
Calcineurin,
Skin,
Database,
STAR,
FY,
Aesthetics,
Acne,
Sculptra,
Prurigo nodularis,
Defense,
FACE,
European Medicines Agency,
Council,
Congress,
Pimple,
GAIN,
Atopic dermatitis,
Sleep,
ESG,
Benzoyl peroxide,
George Washington University,
American Academy,
Marketing,
Health Canada,
Core,
Patient satisfaction,
FDA,
Quality of life,
Ageing,
Food,
IL-31,
Risk,
AAD,
Patient,
Restylane,
Pharmaceutical industry 2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.
Key Points:
- 2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.
- On 26 June 2023, Galderma announced a private placement of approximately 1 B USD from a group consisting of current shareholders, new investors, as well as management.
- Cetaphil, with over 75 years of heritage in sensitive skincare, surpassed a record 1 B USD in net sales in 2023.
- In 2023, Galderma further consolidated its ESG profile by rolling out a dedicated executive-level ESG oversight and instituting the ESG Council.
Retrieved on:
Wednesday, February 28, 2024
Research,
Clinical Trials,
Biotechnology,
Managed Care,
Health,
Cosmetics,
Pharmaceutical,
Retail,
Science,
Acne,
Nemolizumab,
Pacific Ocean,
Atopic dermatitis,
Prurigo nodularis,
Hyperhidrosis,
Dermatology,
Skin,
Consultant,
AAD,
Marriott Marquis,
Safety,
Patient,
Itch,
START,
American Academy,
Medical device Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
Key Points:
- Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
- “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
- The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
- *All presenters are paid consultants or employees of Galderma.
Retrieved on:
Wednesday, February 14, 2024
Lifestyle,
Biotechnology,
FDA,
Health,
Pharmaceutical,
Cosmetics,
Research,
Retail,
Consumer,
Science,
Clinical Trials,
Nemolizumab,
Quality of life,
Atopic dermatitis,
Food,
Prurigo nodularis,
File,
Safety,
Prurigo,
European Medicines Agency,
Sleep,
Patient,
Diagnosis,
Breakthrough therapy,
Itch,
Priority review This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023.
Key Points:
- This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023.
- Priority Review is granted for medicines that would significantly improve the treatment, diagnosis or prevention of serious conditions.
- The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.
- “The relentless itch experienced by many people living with prurigo nodularis and atopic dermatitis has a significant impact on their overall quality of life.
Retrieved on:
Thursday, February 8, 2024
Fashion,
Cosmetics,
Entertainment,
Retail,
Health,
Other Health,
Events,
Concerts,
Partnership,
Magic,
Fashion week,
Season,
Research,
Clothing,
MD,
Walking,
Sleep,
Wilhelmina Models,
Skin,
Beauty,
OCEAN,
SKIN,
Immersion,
Face,
Dermatology,
New York Fashion Week,
Drink,
NYFW This immersion will put the sensitive skin science behind its formulas to the ‘ultimate skin stress test’ at New York Fashion Week (NYFW).
Key Points:
- This immersion will put the sensitive skin science behind its formulas to the ‘ultimate skin stress test’ at New York Fashion Week (NYFW).
- The delegates will participate in 48 hours of Fashion Week events and activations putting Cetaphil’s sensitive skincare formulas to the test.
- New York Fashion Week is the perfect place to put the brand at the forefront of where fashion, beauty and skincare intersect.”
The initiative includes partnerships with contemporary fashion brand Alice + Olivia , modeling and talent agency Wilhelmina International Inc. and global fashion and media brand, Highsnobiety .
- The space will serve as a fashion-forward sensitive skin sanctuary where New Yorkers can relax and refuel amidst the hustle and bustle of Fashion Week.
